Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development

Ricardo Costa*, Ami N. Shah, Cesar A. Santa-Maria, Marcelo R. Cruz, Devalingam Mahalingam, Benedito A. Carneiro, Young Kwang Chae, Massimo Cristofanilli, William J. Gradishar, Francis J. Giles

*Corresponding author for this work

Research output: Contribution to journalReview article

52 Scopus citations

Abstract

Triple negative breast cancer (TNBC) accounts for 10–20% of cases in breast cancer. Despite recent advances in the treatment of hormonal receptor+ and HER2+ breast cancers, there are no targeted therapies available for TNBC. Evidence supports that most patients with TNBC express the transmembrane Epidermal Growth Factor Receptor (EGFR). However, early phase clinical trials failed to demonstrate significant activity of EGFR-targeted monoclonal antibodies and/or tyrosine kinase inhibitors. Here, we review the recent discoveries related to the underlying biology of the EGFR pathway in TNBC, clinical progress to date and suggest rational future approaches for investigational therapies in TNBC.

Original languageEnglish (US)
Pages (from-to)111-119
Number of pages9
JournalCancer Treatment Reviews
Volume53
DOIs
StatePublished - Feb 1 2017

Keywords

  • Epidermal Growth Factor Receptor
  • Targeted therapy
  • Triple negative breast cancer
  • mTOR

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development'. Together they form a unique fingerprint.

  • Cite this